

failure, the book provides complete information about testing (notably, about newer imaging techniques and assessments of myocardial viability) and possible surgical interventions.

Some other limitations of the book should be noted. As in most discussions of heart failure, the distinction between systolic dysfunction and heart failure without systolic dysfunction is sometimes lost; the author of the chapter on epidemiology tends to discuss heart failure in general, but the authors of the chapters on therapeutic strategies focus on patients with the well-studied systolic dysfunction. The book does not focus on pathophysiology and is not designed to bring the reader up-to-date on what is known about the mechanisms of heart failure. Most regrettably, however, it misses the opportunity to provide insight on how the inevitable tension between medical and surgical treatments should be resolved. Addressing this issue might help physicians look at problems in different ways and reasonably consider all possibilities, thereby improving outcomes.

Stephen S. Gottlieb, M.D.

University of Maryland School of Medicine
Baltimore, MD 21201
sgottlie@medicine.umaryland.edu
Book Reviews Copyright © 2007 Massachusetts Medical Society.

CORRECTION

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes (June 14, 2007;356:2457-71). The fifth and sixth sentences of the first paragraph of the Methods section (page 2458) should have read "Of the remaining 42 studies, 38 reported at least one myocardial infarction, and 23 reported at least one death from cardiovascular causes. In these trials, 15,565 patients were randomly assigned to regimens that included rosiglitazone, and 12,282 were assigned to comparator groups with regimens that did not include rosiglitazone." The last sentence of the third paragraph of the Methods section should have read "In this group of 35 trials, 9507 patients were randomly assigned to receive rosiglitazone, and 5960 patients were assigned to receive various comparator drugs." In Table 1 (page 2461), the subtotal in the rosiglitazone group should have been 9507 rather than 9502, and the subtotal in the control group should have been 5960 rather than 5961, which brings the total number of patients in the rosiglitazone group to 15,565 and the total in the control group to 12,282. In Table 4 (page 2468), the rate of myocardial infarction in the small trials combined should have read "44/10,285" for the rosiglitazone group and "22/6106" for the control group. The rate of myocardial infarction for the ADOPT trial should have read "41/2895 (1.42)" for the control group. Death from cardiovascular causes in the small trials combined should have read "25/6845 (0.36)" for the rosiglitazone group and "7/3980 (0.18)" for the control group, death from cardiovascular causes in the DREAM trial should have read "12/2635

(0.46)" for the rosiglitazone group, and death from cardiovascular causes in the ADOPT trial should have read "5/2895 (0.17)" for the control group. The text and tables have been corrected on the *Journal's* Web site at www.nejm.org.

NOTICES

Notices submitted for publication should contain a mailing address and telephone number of a contact person or department. We regret that we are unable to publish all notices received. Notices also appear on the Journal's Web site (www.nejm.org/meetings). The listings can be viewed in their entirety or searched by location, month, or key word.

AMERICAN ACADEMY OF NEUROLOGY

The following conferences will be held: "Dystonia Workshops" (Houston, Aug. 11; San Diego, CA, Sept. 29; Las Vegas, Nov. 2); "AAN Regional Conferences" (Las Vegas, Nov. 2-4; Miami, Jan. 18-20); and "AAN Annual Meeting" (Chicago, April 12-19).

Contact the American Academy of Neurology, 1080 Montreal Ave., Saint Paul, MN 55116; or call (651) 695-2756; or fax (651) 361-4856; or see <http://www.aan.com>.

UNIVERSITY OF TORONTO

The following meetings will be held: "4th Annual G-I-N Conference 2007: Collaboration in Clinical Practice Guidelines" (Toronto, Aug. 22-25; sponsored by the Guidelines International Network) and "11th International Course on Perforator Flaps" (Halifax, NS, Canada, Sept. 7-10).

Contact the Office of Continuing Education & Professional Development, Faculty of Medicine, University of Toronto, 500 University Ave., Suite 650, Toronto, ON M5G 1V7, Canada; or call (416) 978-2719 or (888) 512-8173; or fax (416) 946-7028; or e-mail ce.med@utoronto.ca; or see <http://www.gin2007.org> and <http://www.perforatorflaps2007.ca>, respectively.

INTERNATIONAL SOCIETY OF CRANIOFACIAL SURGERY

The "ISCFs XII Biennial International Congress" will be held in Salvador, Bahia, Brazil, Aug. 23-25.

Contact Suzanne Eggers, Medical Education Division, ImproMED, 1116 W. Centre Ave., Suite 2, Portage, MI 49024-5318; or call (877) 665-8326 (national) or (269) 329-0651 (Michigan); or fax (269) 329-0505; or e-mail info@iscfscongress.org; or see <http://www.iscfscongress.org>.

MONTEFIORE MEDICAL CENTER—ALBERT EINSTEIN COLLEGE OF MEDICINE

The following courses will be offered: "Clinical Neurology for Psychiatrists" (Los Angeles, Sept. 7-9; New York, Oct. 5-7) and "Psychiatry for Psychiatrists: The Pre-Test" (Los Angeles, Sept. 10 and 11; New York, Oct. 8 and 9).

Contact the Center for CME, Montefiore Medical Center, 3301 Bainbridge Ave., Bronx, NY 10467; or call (718) 920-6674; or e-mail cme@montefiore.org; or see <http://www.cnfp.org>.

THE JOURNAL'S WEB AND E-MAIL ADDRESSES:

For letters to the Editor: authors.nejm.org

For information about the status of a submitted manuscript:
authors.nejm.org

To submit a meeting notice: meetingnotices@nejm.org

The *Journal's* Web pages: www.nejm.org